Impact of intratumoral heterogeneity on the metabolic profiling of breast cancer tissue using high‐resolution magic angle spinning magnetic resonance spectroscopy

2021 ◽  
Author(s):  
Ji Soo Choi ◽  
Dahye Yoon ◽  
Kyunghwa Han ◽  
Ja Seoug Koo ◽  
Suhkmann Kim ◽  
...  
2002 ◽  
Vol 15 (5) ◽  
pp. 327-337 ◽  
Author(s):  
Beathe Sitter ◽  
Ursula Sonnewald ◽  
Manfred Spraul ◽  
Hans E. Fjösne ◽  
Ingrid S. Gribbestad

Medicine ◽  
2016 ◽  
Vol 95 (15) ◽  
pp. e3398 ◽  
Author(s):  
Vivian Youngjean Park ◽  
Dahye Yoon ◽  
Ja Seung Koo ◽  
Eun-Kyung Kim ◽  
Seung Il Kim ◽  
...  

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 710-710
Author(s):  
Melissa Jessica Huynh ◽  
Andrew Gusev ◽  
Francesco Palmas ◽  
Lindsey Vandergrift ◽  
Chin-Lee Wu ◽  
...  

710 Background: Renal cell carcinoma (RCC) is a metabolic disease, with the various subtypes exhibiting aberrations in different metabolic pathways. Metabolomics may offer greater sensitivity for revealing disease biology than evaluation of tissue morphology. In this study, we investigate the metabolomic profile of RCC using high resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS). Methods: Tissue samples were obtained from radical or partial nephrectomy specimens that were fresh frozen & stored at -80ºC. Tissue HRMAS MRS was performed by a Bruker AVANCE spectrometer. Metabolomic profiles of RCC & adjacent benign renal tissue were compared, and false discovery rates (FDR) were used to account for multiple testing. Regions of interest (ROI) with FDR < 0.05 were selected as potential predictors of malignancy. The Wilcoxon rank sum test was used to compare median MRS relative intensities for the candidate predictors. Logistic regression was used to determine odds ratios for risk of malignancy based on abundance of each metabolite. Results: There were 38 RCC (16 clear cell, 11 papillary, 11 chromophobe) & 13 adjacent normal tissue specimens (matched pairs). Metabolic predictors of malignancy based on FDR include histidine, phenylalanine, phosphocholine, serine, phosphocreatine, creatine, glycerophosphocholine, valine, glycine, myo-inositol, scylla-inositol, taurine, glutamine, spermine, acetoacetate & lactate. Higher levels of spermine, histidine & phenylalanine at 3.15-3.13 ppm were associated with a decreased risk of RCC (OR 4x10−5, 95% CI 7.42x10−8, 0.02), while 2.84-2.82 ppm increased the risk of malignant pathology (OR 7158.67, 95% CI 6.3, 8.3x106), and the specific metabolites characterizing this region remain to be identified. Tumor stage did not appear to affect the metabolomics of malignant tumors, suggesting that metabolites are more dependent on histologic subtype. Conclusions: HRMAS-MRS identified many metabolites that may predict RCC. We demonstrated that those in the 3.14-3.13 ppm ROI were present in lower levels in RCC, while higher levels of metabolites in the 2.84-2.82 ppm ROI substantially increased the risk of RCC.


Sign in / Sign up

Export Citation Format

Share Document